PLAC test for identification of individuals at increased risk for coronary heart disease.
Recent advances in cardiovascular research point to a critical role of inflammatory processes in the etiology of cardiovascular disease. This has led to the discovery of novel inflammatory biomarkers, which may be useful as additional screening tools for the identification of individuals at increased risk of coronary heart disease. One such novel inflammatory biomarker is lipoprotein-associated phospholipase A(2). This review discusses the recent development of a US Food and Drug Administration-approved blood test for lipoprotein-associated phospholipase A(2) (PLAC test, diaDexus, Inc.) and its efficacy as a predictive biomarker of risk for cardiovascular disease. More specifically, the article addresses the potential target group most likely to benefit from this new screening test and provides a prospective scenario for its implementation.
Hoogeveen
Ron C
RC
Baylor College of Medicine, Section of Atherosclerosis & Lipoprotein Research, Department of Medicine, Center for Cardiovascular Disease Prevention, Houston, TX 77030, USA. ronh@bcm.tmc.edu
Ballantyne
Christie M
CM
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D015415:Biomarkers; D003327:Coronary Disease / Q000175:diagnosis* / Q000378:metabolism*; D006801:Humans; D010741:Phospholipases A / Q000097:blood*; D011379:Prognosis; D012307:Risk Factors; D020521:Stroke / Q000175:diagnosis / Q000378:metabolism
D015415:Biomarkers; D010741:Phospholipases A; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase